NRx Pharmaceuticals Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression

RADNOR, Pa., April 30, 2024, NRx Pharmaceuticals, Inc. ( " NRx Pharmaceuticals " , the " Company " ), a clinical stage pharmaceutical company today that its Breakthrough Therapy designated investigational drug NRX-101 vs lurasidone demonstrated a...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials